Skip to main content

Market Overview

Par Pharma Begins Shipping Generic Atacand HCT


Par Pharmaceutical Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive U.S. supply and distribution agreement with AstraZeneca (NYSE: AZN) to distribute the authorized generic version of AstraZeneca's Atacand HCT^® (candesartan cilexetil/hydrochlorothiazide). Par has begun shipping 16/12.5 mg, 32/12.5 mg and 32/25 mg strengths of candesartan cilexetil/ hydrochlorothiazide tablets. According to IMS Health data, annual U.S. sales of Atacand HCT^® are approximately $61 million.


Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at